BRIGHTFOCUS FOUNDATION: Form 990, tax year 2011

View the entire original 990 at ProPublica ↗

Organization: BRIGHTFOCUS FOUNDATION (EIN 23-7337229)
Tax period: 2011-04-01 to 2012-03-31
Filed: 2012-08-03
IRS object ID: 201212169349300246
Schema version: 2011v1.2
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Timestamp	2012-08-03T13:47:30-05:00	Timestamp
Tax Period End Date	2012-03-31	TaxPeriodEndDate

Preparer Firm PreparerFirm

Field	Value	IRS element (for citing)
EIN	521511275	EIN

Preparer Firm Business Name PreparerFirmBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	Raffa PC	BusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

Field	Value	IRS element (for citing)
Address Line1	1899 L Street NW Suite 900	AddressLine1
City	Washington	City
State	DC	State
ZIP Code	20036	ZIPCode

Field	Value	IRS element (for citing)
Return Type	990	ReturnType
Tax Period Begin Date	2011-04-01	TaxPeriodBeginDate

Filer Filer

Field	Value	IRS element (for citing)
EIN	237337229	EIN

Name Name

Field	Value	IRS element (for citing)
Business Name Line1	American Health Assistance Foundation	BusinessNameLine1

Field	Value	IRS element (for citing)
Name Control	AMER	NameControl
Phone	3019483244	Phone

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	22512 Gateway Center Drive	AddressLine1
City	Clarksburg	City
State	MD	State
ZIP Code	20871	ZIPCode

Officer Officer

Field	Value	IRS element (for citing)
Name	Stacy Pagos Haller	Name
Title	President/CEO	Title
Phone	3019483244	Phone
Date Signed	2012-08-01	DateSigned
Authorize Third Party	1	AuthorizeThirdParty

Preparer Preparer

Field	Value	IRS element (for citing)
Name	Frank H Smith	Name
PTIN	P00639053	PTIN
Phone	2028225000	Phone
Date Prepared	2012-08-03	DatePrepared

Field	Value	IRS element (for citing)
Tax Year	2011	TaxYear
Build TS	2016-02-24 21:20:13Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Name Of Principal Officer Person	Stacy Pagos Haller	NameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

Field	Value	IRS element (for citing)
Address Line1	22512 Gateway Center Drive	AddressLine1
City	Clarksburg	City
State	MD	State
ZIP Code	20871	ZIPCode

Field	Value	IRS element (for citing)
Gross Receipts	33300158	GrossReceipts
Group Return For Affiliates	0	GroupReturnForAffiliates
Organization501c3	X	Organization501c3
Web Site	www.ahaf.org	WebSite
Type Of Organization Corporation	X	TypeOfOrganizationCorporation
Year Formation	1973	YearFormation
State Legal Domicile	DC	StateLegalDomicile
Activity Or Mission Description	Seeks to eradicate age-related and degenerative diseases.	ActivityOrMissionDescription
Nbr Voting Members Governing Body	11	NbrVotingMembersGoverningBody
Nbr Independent Voting Members	11	NbrIndependentVotingMembers
Total Nbr Employees	49	TotalNbrEmployees
Total Nbr Volunteers	92	TotalNbrVolunteers
Total Gross UBI	0	TotalGrossUBI
Net Unrelated Business Txbl Income	0	NetUnrelatedBusinessTxblIncome
Contributions Grants Prior Year	18261062	ContributionsGrantsPriorYear
Contributions Grants Current Year	22601859	ContributionsGrantsCurrentYear
Program Service Revenue Prior Year	0	ProgramServiceRevenuePriorYear
Program Service Revenue CY	0	ProgramServiceRevenueCY
Investment Income Prior Year	2575465	InvestmentIncomePriorYear
Investment Income Current Year	696172	InvestmentIncomeCurrentYear
Other Revenue Prior Year	706437	OtherRevenuePriorYear
Other Revenue Current Year	1111974	OtherRevenueCurrentYear
Total Revenue Prior Year	21542964	TotalRevenuePriorYear
Total Revenue Current Year	24410005	TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year	5594209	GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY	5702962	GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year	0	BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY	0	BenefitsPaidToMembersCY
Salaries Etc Prior Year	3157144	SalariesEtcPriorYear
Salaries Etc Current Year	3544993	SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year	476168	TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY	379676	TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year	4771179	TotalFundrsngExpCurrentYear
Other Expense Prior Year	11872123	OtherExpensePriorYear
Other Expenses Current Year	11799045	OtherExpensesCurrentYear
Total Expenses Prior Year	21099644	TotalExpensesPriorYear
Total Expenses Current Year	21426676	TotalExpensesCurrentYear
Revenues Less Expenses Prior Year	443320	RevenuesLessExpensesPriorYear
Revenues Less Expenses CY	2983329	RevenuesLessExpensesCY
Total Assets BOY	37750130	TotalAssetsBOY
Total Assets EOY	39273122	TotalAssetsEOY
Total Liabilities BOY	15113621	TotalLiabilitiesBOY
Total Liabilities EOY	13573560	TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY	22636509	NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY	25699562	NetAssetsOrFundBalancesEOY
Info In Schedule O Part III	X	InfoInScheduleOPartIII
Mission Description	The American Health Assistance Foundation seeks to eradicate age-related degenerative diseases by: advancing research seeking causes, prevention, treatment, and cures; promoting positive behaviors to combat these diseases; and facilitating the public's efforts to assist those who are affected.	MissionDescription
Significant New Program Services	0	SignificantNewProgramServices
Significant Change	0	SignificantChange
Expense	9485998	Expense
Grants	3602962	Grants
Description	Alzheimer's Disease Research (ADR)--ADR annually awards peer-reviewed grants to scientists from institutions worldwide who are conducting biomedical and clinical research on Alzheimer's disease. ADR grants fall into three categories. Standard and pilot awards are intended for established researchers, and postdoctoral research fellowships support scientists who are training to assume the responsibilities of directing their first research laboratory. During the fiscal year ended March 31, 2012, ADR funded 22 new projects, totaling $3,598,962, and awarded a continuing project an additional $4,000. The projects range from advanced genetic studies that aim to identify inheritable risks for Alzheimer's disease through those designed to create new therapeutic interventions against the disease. Additional information about specific projects is in Schedule I. AHAF continues its partnership with the academic journal "Molecular Neurodegeneration" to develop the publication as the official journal of the American Health Assistance Foundation. It publishes technical papers primarily on topics related to the ADR program. As an "open access" journal, there is no fee for readers, and all content is freely available through its website.ADR awards made national headlines in this fiscal year, including high a visibility report suggesting a role for a previously approved drug in combating Alzheimer's disease. This drug will very soon enter human clinical trials. More details are available in the news updates section of the AHAF.org website.ADR provides information about risk factors, preventive measures, diagnosis, treatment, and lifestyle changes for Alzheimer's patients, their families, caregivers, at-risk groups, the media, and the public at large. The program also ensures that target audiences are aware of AHAF-donor-funded Alzheimer's disease research and the latest scientific developments. ADR provides this information through eAlerts, newsletters, social media, informational publications, videos, podcasts, and TV and radio public service announcements (PSAs). Medical and research news updates are routinely posted on the AHAF website and disseminated through print and electronic media.AHAF provides a number of patient education and public information materials in print and PDF formats. Most popular among these publications is "Living with Alzheimer's Disease," a 35-page booklet with information including risk factors and mitigation, causes and treatment of the disease, coping and caregiving strategies, financial and legal planning, and resources for patients and families. Other materials, updated this year, include:1. "Understanding Alzheimer's: It's Not Just Forgetfulness," 2. "Care for the Caregiver: Managing Stress,"3. "Safety and the Older Driver,"4. "Staying Safe: Wandering and the Alzheimer's Patient." 5. 15 fact sheets6. 20 streaming video and audio programsADR publications are available in English and have also been translated by native speakers for Spanish audiences. All new materials are available in PDF on the AHAF website at www.ahaf.org/ADRresources.An ADR PSA, "Understanding this Debilitating Disease," produced in English and Spanish in the prior year, ran nationwide on TV and radio this fiscal year. ADR benefitted from $12,025,766 in donated media services. The informational PSA continues to generate calls, emails, and web visits from people affected by, or interested in, the disease. Members of AHAF's Scientific Affairs division were interviewed for and quoted in several media stories during the year, including Voice of America, Medical Daily, Seattle Post-Intelligencer, and Rochester Post-Bulletin. The ADR newsletter was sent to thousands of constituents three times this year, and information about Alzheimer's disease was included in two editions of the AHAF Insider Report. ADR provided 236 answers to Ask an Expert questions during the year. This question-and-answer forum provides professionally researched answers to questions submitted to AHAF's ADR program. More than 30 eAlerts on Alzheimer's disease were sent to members of ADR's opt-in distribution list. Several messages on Alzheimer's disease were distributed weekly throughout the year on AHAF's social media channels, engaging thousands of followers. ADR mailed awareness-raising materials on Alzheimer's disease to hundreds of thousands of households, with messages focusing on: 1. Symptom recognition and steps the public should take, such as making an appointment with the doctor if any of these symptoms exist.2. Lifestyle choices that promote good health, encouraging readers to take action to reduce the likelihood of the onset of the disease; i.e. exercise your mind by playing board games, cards, and puzzles.3. Research results and treatments available to address Alzheimer's disease.	Description

Activity2 Activity2

Field	Value	IRS element (for citing)
Expense	3024951	Expense
Grants	1000000	Grants
Description	Macular Degeneration Research (MDR)--Through an outreach effort in key trade publications and information distribution at major conferences for eye researchers, MDR encourages junior- and senior-level scientists around the world to apply for its prestigious macular degeneration research grant program. MDR annually offers grants to scientists through a sophisticated peer-review process managed by the MDR Scientific Review Committee. This group of the field's leading scientists bases these decisions on scientific merit using a rigorous evaluation system. During the fiscal year ending March 31, 2012, MDR awarded $1,000,000 in grants to 10 new projects that range from studies to understand the influence of racial identity on increased risk for macular degeneration to those aimed at designing new cell-based therapies to target and eliminates the molecular changes that lead to macular degeneration. Additional details about specific projects are in Schedule I. MDR-funded projects were featured in media articles, including one in which scientists developed a new synthetic form of vitamin A. This product has now been licensed to a pharmaceutical company for clinical trials aimed at providing a treatment for the dry, and currently untreatable, form of macular degeneration. More details on this and other successful programs achieved through MDR funding are available in the news updates section of the AHAF.org website.MDR's Children's Corner for Macular Degeneration (CCMD), a website aimed at teaching children about the degenerative disease through stories, interactive games, and sharing activities, continues to help family members learn about the disease. AHAF created TV and radio PSAs about CCMD in English and Spanish, which aired throughout the year on stations across the country. The campaign received more than 45 million impressions and drove thousands of people to the CCMD website and to call and email AHAF. New educational materials supported this outreach effort. MDR benefitted from $5,788,439 in donated media services. MDR proactively disseminates information to the public directly and via traditional and social media. Other channels include email, newsletters, publications, videos, and podcasts. This includes information on risk factors, preventive measures, the progression of the disease, available medical treatments, suggestions for adapting to low vision, and new research developments. Medical and research news updates on macular degeneration are routinely posted on the AHAF website and distributed to interested audiences.MDR continued to distribute high quality informative materials, including updated editions of "Macular Degeneration: The Essential Facts," the comprehensive booklet "Living with Macular Degeneration," "Safety and the Older Driver," and the "Low Vision Resource List." MDR created a set of nine fact sheets in English and Spanish as well as new streaming media content. The organization now provides a macular degeneration animated video series, donated by Eyemaginations. Three editions of the MDR newsletter were sent to interested constituents by mail and email. All MDR publications are in large print and available in PDF in English and Spanish on the AHAF website at www.ahaf.org/MDRresources. The AHAF Insider Report, which included information about macular degeneration, was distributed twice this year. Answers to 280 Ask an Expert questions on macular degeneration were provided via email and on the AHAF website during the year. More than 20 eAlerts were sent to members of the macular degeneration opt-in distribution list. Each week AHAF distributed a range of messages on macular degeneration using its social media channels, engaging thousands of followers. AHAF's Scientific Affairs division staff members were interviewed for media stories, including serving as the featured expert in several vision-oriented radio programs, which helped increase awareness of the organization and raise its scientific credibility related to eye disease.MDR mailed awareness-raising materials on macular degeneration to tens of thousands of households, with highlighted messages including: 1. Identifying symptoms and recommending steps the public can take, such as getting comprehensive eye exams regularly.2. Lifestyle choices that promote good health and reduce the likelihood of disease, like eating an "eye healthy" diet.3. Current research and the preventive measures that can be taken to help reduce the risk of macular degeneration.	Description

Activity3 Activity3

Field	Value	IRS element (for citing)
Expense	1545057	Expense
Grants	1100000	Grants
Description	National Glaucoma Research (NGR)--NGR grants are available to glaucoma researchers worldwide. NGR places special emphasis on encouraging applications from young scientists and those with cutting-edge ideas. Annual grant applications are peer-reviewed, and recipient selections are based on scientific merit. During the fiscal year ending March 31, 2012, NGR awarded $1,100,000 for 11 new projects that range from examinations of the roots of glaucoma in the brain to studies designed to alleviate the buildup of pressure within the eye, a documented risk factor for glaucoma. Additional details about specific projects are in Schedules F & I.NGR-funded research was recognized by the media this year, including new NGR supported data that suggest a targeted x-ray treatment for protection of nerves from glaucomatous damage. More details are available in the news updates section of the AHAF.org website.The NGR communications outreach program encourages people to take preventive measures (e.g., scheduling regular eye exams), to adhere to medication regimens, and to understand risk factors and symptoms. It also provides information on treatments as well as resources for adjusting to low vision. Regular updates on current glaucoma research and the latest study results are disseminated to the public directly and through the web, email, and social and traditional media. As a curator of critical news in the field, NGR distributed 13 eAlerts to people interested in glaucoma research in this fiscal year. NGR responded to 250 Ask an Expert questions, sending emails directly to the inquirers and posting answers on the website for all to see. Updated versions of two NGR publications--"Essential Facts on Glaucoma" and "Living with Glaucoma"--continue to be in great demand. Other popular publications include "Safety and the Older Driver," the new "Low Vision Resource List," and five glaucoma fact sheets in English and Spanish. All NGR materials are in large print and available in PDF in English and Spanish at www.ahaf.org/NGRresources. The site also features six podcasts and ten videos produced this year as well as a series of seven videos describing glaucoma risk factors, symptoms, diagnosis, treatments, lifestyle changes, and research. This video series, produced with the MonkeySee network, is available through more than 1500 online outlets as well as the AHAF site and YouTube. AHAF now delivers an animated video series about glaucoma through Eyemaginations. Three editions of the NGR newsletter were mailed to readers during the year and posted to the AHAF website, and information about glaucoma was included in two editions of the AHAF Insider Report. With one of the most active social media followings in the glaucoma field, NGR communicated news and information several times each week via these networking channels. The AHAF PSA titled "You Have Questions; We Have Answers" continued airing this year. Produced in English and Spanish, it ran on TV, radio, and the Internet, raising awareness about glaucoma and generating calls, emails, and web visits. NGR benefitted from $1,231,031 in donated media services. AHAF's Scientific Affairs division staff members were interviewed for media stories, including being the featured expert in several vision-oriented radio programs, which helped increase awareness of the organization and raise its scientific credibility related to eye disease. NGR mailed awareness-raising materials on glaucoma to tens of thousands of households, focusing on: 1. Symptom recognition, urging people to schedule an eye examination for early detection, as symptoms are not always noticed.2. Lifestyle choices that promote good health and steps the public can take to reduce the likelihood of the onset of the disease; i.e. eat an "eye healthy" diet.3. Treatments and medicines to control the disease and any actions that can be taken to assist people living with glaucoma and their families.	Description

Field	Value	IRS element (for citing)
Total Program Service Expense	14056006	TotalProgramServiceExpense
Described In501 C3	1	DescribedIn501C3
Schedule B Required	1	ScheduleBRequired
Political Activities	0	PoliticalActivities
Lobbying Activities	0	LobbyingActivities
Subject To Proxy Tax	0	SubjectToProxyTax
Donor Advised Funds	0	DonorAdvisedFunds
Conservation Easements	0	ConservationEasements
Collections Of Art	0	CollectionsOfArt
Credit Counseling	0	CreditCounseling
Term Or Permanent Endowments	1	TermOrPermanentEndowments
Report Land Bldg Equip	1	ReportLandBldgEquip
Report Invest Oth Securities	1	ReportInvestOthSecurities
Report Prog Rel Invest	0	ReportProgRelInvest
Report Other Assets	0	ReportOtherAssets
Report Other Liabilities	1	ReportOtherLiabilities
Report Fin48 Footnote	1	ReportFin48Footnote
Independent Audit Financial Stmt	1	IndependentAuditFinancialStmt
Consolidated Audit Financial Stmt	0	ConsolidatedAuditFinancialStmt
School	0	School
Foreign Office	0	ForeignOffice
Foreign Activities	1	ForeignActivities
More Than5000 K To Organizations	1	MoreThan5000KToOrganizations
More Than5000 K To Individuals	0	MoreThan5000KToIndividuals
Professional Fundraising	1	ProfessionalFundraising
Fundraising Activities	1	FundraisingActivities
Gaming	0	Gaming
Hospital	0	Hospital
Grants To Organizations	1	GrantsToOrganizations
Grants To Individuals	0	GrantsToIndividuals
Schedule J Required	1	ScheduleJRequired
Tax Exempt Bonds	0	TaxExemptBonds
Excess Benefit Transaction	0	ExcessBenefitTransaction
Prior Excess Benefit Transaction	0	PriorExcessBenefitTransaction
Loan To Officer Or DQP	0	LoanToOfficerOrDQP
Grant To Related Person	0	GrantToRelatedPerson
Bsnss Rltnshp With Organization	0	BsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family Member	0	BsnssRltnshpThruFamilyMember
Officer Entity With Bsnss Rltnshp	0	OfficerEntityWithBsnssRltnshp
Deductible Non Cash Contributions	1	DeductibleNonCashContributions
Deductible Contributions Of Art	0	DeductibleContributionsOfArt
Terminated	0	Terminated
Partial Liquidation	0	PartialLiquidation
Disregarded Entity	1	DisregardedEntity
Related Entity	0	RelatedEntity
Related Org Controlled Entity	0	RelatedOrgControlledEntity
Transaction Related Entity	0	TransactionRelatedEntity
Transfers To Exempt Non Chrtbl Org	0	TransfersToExemptNonChrtblOrg
Activities Conducted Partnership	0	ActivitiesConductedPartnership
Schedule O Required	1	ScheduleORequired
Number Forms Transmitted With1096	223	NumberFormsTransmittedWith1096
Number W2 G Included	0	NumberW2GIncluded
Compliance With Backup Witholding	1	ComplianceWithBackupWitholding
Number Of Employees	49	NumberOfEmployees
Employment Tax Returns Filed	1	EmploymentTaxReturnsFiled
Unrelated Business Income	0	UnrelatedBusinessIncome
Foreign Financial Account	0	ForeignFinancialAccount
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTrans
Taxable Party Notification	0	TaxablePartyNotification
Non Deductible Contributions	0	NonDeductibleContributions
Quid Pro Quo Contributions	1	QuidProQuoContributions
Quid Pro Quo Disclosure	1	QuidProQuoDisclosure
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOf
Funds To Pay Premiums	0	FundsToPayPremiums
Premiums Paid	0	PremiumsPaid
Indoor Tanning Services	0	IndoorTanningServices
Info In Schedule O Part VI	X	InfoInScheduleOPartVI
Nbr Voting Governing Body Members	11	NbrVotingGoverningBodyMembers
Number Independent Voting Members	11	NumberIndependentVotingMembers
Family Or Business Relationship	0	FamilyOrBusinessRelationship
Delegation Of Management Duties	0	DelegationOfManagementDuties
Changes To Organizing Docs	1	ChangesToOrganizingDocs
Material Diversion Or Misuse	0	MaterialDiversionOrMisuse
Members Or Stockholders	0	MembersOrStockholders
Election Of Board Members	0	ElectionOfBoardMembers
Decisions Subject To Approval	0	DecisionsSubjectToApproval
Minutes Of Governing Body	1	MinutesOfGoverningBody
Minutes Of Committees	1	MinutesOfCommittees
Officer Mailing Address	0	OfficerMailingAddress
Local Chapters	0	LocalChapters
Form990 Provided To Governing Body	1	Form990ProvidedToGoverningBody
Conflict Of Interest Policy	1	ConflictOfInterestPolicy
Annual Disclosure Covered Persons	1	AnnualDisclosureCoveredPersons
Regular Monitoring Enforcement	1	RegularMonitoringEnforcement
Whistleblower Policy	1	WhistleblowerPolicy
Document Retention Policy	1	DocumentRetentionPolicy
Compensation Process CEO	1	CompensationProcessCEO
Compensation Process Other	0	CompensationProcessOther
Investment In Joint Venture	0	InvestmentInJointVenture
States Where Copy Of Return Is Filed	AK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AZ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	FL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	GA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	HI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	IL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	ME	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MD	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NJ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NM	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	ND	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	PA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	RI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	SC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	TN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	UT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	VA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WV	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WI	StatesWhereCopyOfReturnIsFiled
Own Website	X	OwnWebsite
Upon Request	X	UponRequest

The Books Are In Care Of TheBooksAreInCareOf

Name Business NameBusiness

Field	Value	IRS element (for citing)
Business Name Line1	David F Marks CPA CMA	BusinessNameLine1

Field	Value	IRS element (for citing)
Telephone Number	3019483244	TelephoneNumber

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	22512 Gateway Center Drive	AddressLine1
City	Clarksburg	City
State	MD	State
ZIP Code	20871	ZIPCode

Form990 Part VII Section A Form990PartVIISectionA (17 entries)

TitleTitle	Average Hours Per WeekAverageHoursPerWeek	Individual Trustee Or DirectorIndividualTrusteeOrDirector	OfficerOfficer	Reportable Comp From OrganizationReportableCompFromOrganization	Reportable Comp From Related OrgsReportableCompFromRelatedOrgs	Other CompensationOtherCompensation	Key EmployeeKeyEmployee	Highest Compensated EmployeeHighestCompensatedEmployee
Brian K Regan PhD
Chairman	10.00	X	X	0	0	0
Grace Frisone
Vice Chairman	10.00	X	X	0	0	0
Nicholas W Raymond
Treasurer	12.00	X	X	0	0	0
Michael H Barnett Esq
Secretary	3.00	X	X	0	0	0
Scott Rodgville CPA
Assist. Treasurer	3.00	X	X	0	0	0
June Kinoshita
Director	5.00	X		0	0	0
Judith Lee
Director	5.00	X		0	0	0
Diane Marcello
Director	3.00	X		0	0	0
Henry Pownall PhD
Director	2.00	X		0	0	0
Jonathan Rice Esq
Director	3.00	X		0	0	0
Eltjo R Ed Schoonveld
Director	5.00	X		0	0	0
Stacy Pagos Haller
President/CEO	55.00		X	285422	0	52426
Donna Callison
VP, Development	45.00			162032	0	24794	X
Guy Eakin Ph D
VP, Scientific Affairs	45.00			120636	0	45322		X
David F Marks CPA CMA
VP, Finance & Administration	45.00			146059	0	39284		X
Melissa May
VP, Communications	45.00			134092	0	16550		X
June Falb
Former Dir. Leadership Gifts	35.00			123537	0	8142		X

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	971778	TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs	0	TotalReportableCompFrmRltdOrgs
Total Other Compensation	186518	TotalOtherCompensation
Number Individuals GT100 K	6	NumberIndividualsGT100K
Formers Listed	0	FormersListed
Total Comp GT150 K	1	TotalCompGT150K
Compensation From Other Sources	0	CompensationFromOtherSources

Contractor Compensation ContractorCompensation (5 entries)

Address Line1AddressOfContractor/AddressUS/AddressLine1	CityAddressOfContractor/AddressUS/City	StateAddressOfContractor/AddressUS/State	ZIP CodeAddressOfContractor/AddressUS/ZIPCode	Description Of ServicesDescriptionOfServices	CompensationCompensation
WildeLW Robbins Associates Inc
201 Summer Street	Holliston	MA	01746	Direct mail consulting	3173768
Quad Graphics Inc
5550 South 108th Street	West Allis	WI	53214	Mailshop and printing	491583
SCA Direct Inc
11208 Waples Mill Rd Suite 106	Fairfax	VA	22030	Direct mail consulting	398440
Blackbaud Inc
2000 Daniel Island Drive	Charleston	SC	29492	Database management	353349
Tri-State Envelope Corporation
1 Orgler Place	Ashland	PA	17921	Printing	323448

Field	Value	IRS element (for citing)
Number Of Contractors GT100 K	8	NumberOfContractorsGT100K
Federated Campaigns	23008	FederatedCampaigns
Fundraising Events	42845	FundraisingEvents
All Other Contributions	22536006	AllOtherContributions
Noncash Contributions	56792	NoncashContributions
Total Contributions	22601859	TotalContributions

Investment Income InvestmentIncome

Field	Value	IRS element (for citing)
Total Revenue Column	515428	TotalRevenueColumn
Exclusion	$515,428	ExclusionAmount

Royalties Revenue RoyaltiesRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	266240	TotalRevenueColumn
Exclusion	$266,240	ExclusionAmount

Gross Rents GrossRents

Field	Value	IRS element (for citing)
Real	563755	Real

Less Rental Expenses LessRentalExpenses

Field	Value	IRS element (for citing)
Real	42967	Real

Rental Income Or Loss RentalIncomeOrLoss

Field	Value	IRS element (for citing)
Real	520788	Real

Net Rental Income Or Loss NetRentalIncomeOrLoss

Field	Value	IRS element (for citing)
Total Revenue Column	520788	TotalRevenueColumn
Exclusion	$520,788	ExclusionAmount

Gross Amount Sales Assets GrossAmountSalesAssets

Field	Value	IRS element (for citing)
Securities	9001064	Securities

Less Cost Oth Basis Sales Expenses LessCostOthBasisSalesExpenses

Field	Value	IRS element (for citing)
Securities	8820320	Securities

Gain Or Loss GainOrLoss

Field	Value	IRS element (for citing)
Securities	180744	Securities

Net Gain Or Loss Investments NetGainOrLossInvestments

Field	Value	IRS element (for citing)
Total Revenue Column	180744	TotalRevenueColumn
Exclusion	$180,744	ExclusionAmount

Field	Value	IRS element (for citing)
Gross Income Fundraising Events	11659	GrossIncomeFundraisingEvents
Cntrbtns Rprtd Fundraising Events	42845	CntrbtnsRprtdFundraisingEvents
Fundraising Direct Expenses	26866	FundraisingDirectExpenses

Net Income From Fundraising Events NetIncomeFromFundraisingEvents

Field	Value	IRS element (for citing)
Total Revenue Column	-15207	TotalRevenueColumn
Exclusion	-$15,207	ExclusionAmount

Other Revenue Misc OtherRevenueMisc (2 entries)

DescriptionDescription	Business CodeBusinessCode	Total Revenue ColumnTotalRevenueColumn	ExclusionExclusionAmount
Rental settlement	900099	340137	$340,137
Other	900099	16	$16

Field	Value	IRS element (for citing)
Total Other Revenue	340153	TotalOtherRevenue

Total Revenue TotalRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	24410005	TotalRevenueColumn
Related Or Exempt Function Income	0	RelatedOrExemptFunctionIncome
Unrelated Business Revenue	0	UnrelatedBusinessRevenue
Exclusion	$1,808,146	ExclusionAmount

Grants To Domestic Orgs GrantsToDomesticOrgs

Field	Value	IRS element (for citing)
Total	5602962	Total
Program Services	5602962	ProgramServices

Foreign Grants ForeignGrants

Field	Value	IRS element (for citing)
Total	100000	Total
Program Services	100000	ProgramServices

Comp Current Officers Directors CompCurrentOfficersDirectors

Field	Value	IRS element (for citing)
Total	537258	Total
Program Services	214121	ProgramServices
Management And General	124839	ManagementAndGeneral
Fundraising	198298	Fundraising

Other Salaries And Wages OtherSalariesAndWages

Field	Value	IRS element (for citing)
Total	2232803	Total
Program Services	1103157	ProgramServices
Management And General	718306	ManagementAndGeneral
Fundraising	411340	Fundraising

Pension Plan Contributions PensionPlanContributions

Field	Value	IRS element (for citing)
Total	235711	Total
Program Services	116457	ProgramServices
Management And General	75830	ManagementAndGeneral
Fundraising	43424	Fundraising

Other Employee Benefits OtherEmployeeBenefits

Field	Value	IRS element (for citing)
Total	353624	Total
Program Services	174714	ProgramServices
Management And General	113763	ManagementAndGeneral
Fundraising	65147	Fundraising

Payroll Taxes PayrollTaxes

Field	Value	IRS element (for citing)
Total	185597	Total
Program Services	91698	ProgramServices
Management And General	59708	ManagementAndGeneral
Fundraising	34191	Fundraising

Fees For Services Legal FeesForServicesLegal

Field	Value	IRS element (for citing)
Total	114604	Total
Program Services	20718	ProgramServices
Management And General	93886	ManagementAndGeneral

Fees For Services Accounting FeesForServicesAccounting

Field	Value	IRS element (for citing)
Total	73390	Total
Program Services	29436	ProgramServices
Management And General	18944	ManagementAndGeneral
Fundraising	25010	Fundraising

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	379676	Total
Fundraising	379676	Fundraising

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

Field	Value	IRS element (for citing)
Total	135815	Total
Management And General	135815	ManagementAndGeneral

Fees For Services Other FeesForServicesOther

Field	Value	IRS element (for citing)
Total	691350	Total
Program Services	609584	ProgramServices
Management And General	38295	ManagementAndGeneral
Fundraising	43471	Fundraising

Office Expenses OfficeExpenses

Field	Value	IRS element (for citing)
Total	445579	Total
Program Services	137724	ProgramServices
Management And General	190345	ManagementAndGeneral
Fundraising	117510	Fundraising

Information Technology InformationTechnology

Field	Value	IRS element (for citing)
Total	603218	Total
Program Services	325606	ProgramServices
Management And General	162354	ManagementAndGeneral
Fundraising	115258	Fundraising

Occupancy Occupancy

Field	Value	IRS element (for citing)
Total	365716	Total
Program Services	181694	ProgramServices
Management And General	121874	ManagementAndGeneral
Fundraising	62148	Fundraising

Travel Travel

Field	Value	IRS element (for citing)
Total	219947	Total
Program Services	128429	ProgramServices
Management And General	55538	ManagementAndGeneral
Fundraising	35980	Fundraising

Conferences Meetings ConferencesMeetings

Field	Value	IRS element (for citing)
Total	43239	Total
Program Services	39136	ProgramServices
Management And General	2491	ManagementAndGeneral
Fundraising	1612	Fundraising

Depreciation Depletion DepreciationDepletion

Field	Value	IRS element (for citing)
Total	257777	Total
Program Services	126771	ProgramServices
Management And General	82675	ManagementAndGeneral
Fundraising	48331	Fundraising

Insurance Insurance

Field	Value	IRS element (for citing)
Total	67276	Total
Program Services	33145	ProgramServices
Management And General	20316	ManagementAndGeneral
Fundraising	13815	Fundraising

Other Expenses OtherExpenses (4 entries)

DescriptionDescription	TotalTotal	Program ServicesProgramServices	Management And GeneralManagementAndGeneral	FundraisingFundraising
Direct mail postage	3650504	1998724	230749	1421031
Direct mail print/publ.	2636234	1422490	162221	1051523
Direct mail comp./mails	1244891	708208	81761	454922
Direct mail consulting	625045	560283	64762

All Other Expenses AllOtherExpenses

Field	Value	IRS element (for citing)
Total	624460	Total
Program Services	330949	ProgramServices
Management And General	45019	ManagementAndGeneral
Fundraising	248492	Fundraising

Total Functional Expenses TotalFunctionalExpenses

Field	Value	IRS element (for citing)
Total	21426676	Total
Program Services	14056006	ProgramServices
Management And General	2599491	ManagementAndGeneral
Fundraising	4771179	Fundraising

Field	Value	IRS element (for citing)
Joint Costs	X	JointCosts

Total Joint Costs TotalJointCosts

Field	Value	IRS element (for citing)
Total	9160810	Total
Program Services	5020654	ProgramServices
Management And General	584512	ManagementAndGeneral
Fundraising	3555644	Fundraising

Cash Non Interest Bearing CashNonInterestBearing

Field	Value	IRS element (for citing)
BOY	3151374	BOY
EOY	3573854	EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

Field	Value	IRS element (for citing)
BOY	481803	BOY
EOY	436317	EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

Field	Value	IRS element (for citing)
BOY	2575645	BOY
EOY	5583310	EOY

Other Notes Loans Receivable Net OtherNotesLoansReceivableNet

Field	Value	IRS element (for citing)
BOY	316096	BOY
EOY	239858	EOY

Inventories For Sale Or Use InventoriesForSaleOrUse

Field	Value	IRS element (for citing)
BOY	134231	BOY
EOY	18768	EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

Field	Value	IRS element (for citing)
BOY	90659	BOY
EOY	180776	EOY

Field	Value	IRS element (for citing)
Land Buildings Equipment Basis	11012535	LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec	2304600	LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

Field	Value	IRS element (for citing)
BOY	8884790	BOY
EOY	8707935	EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

Field	Value	IRS element (for citing)
BOY	18659162	BOY
EOY	17214019	EOY

Investments Other Securities InvestmentsOtherSecurities

Field	Value	IRS element (for citing)
BOY	2580114	BOY
EOY	2230062	EOY

Other Assets Total OtherAssetsTotal

Field	Value	IRS element (for citing)
BOY	876256	BOY
EOY	1088223	EOY

Total Assets TotalAssets

Field	Value	IRS element (for citing)
BOY	37750130	BOY
EOY	39273122	EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

Field	Value	IRS element (for citing)
BOY	1003163	BOY
EOY	711208	EOY

Grants Payable GrantsPayable

Field	Value	IRS element (for citing)
BOY	11181827	BOY
EOY	10348020	EOY

Tax Exempt Bond Liabilities TaxExemptBondLiabilities

Field	Value	IRS element (for citing)
BOY	1310000	BOY

Mort Notes Pybl Secured Invest Prop MortNotesPyblSecuredInvestProp

Field	Value	IRS element (for citing)
EOY	841601	EOY

Other Liabilities OtherLiabilities

Field	Value	IRS element (for citing)
BOY	1618631	BOY
EOY	1672731	EOY

Total Liabilities TotalLiabilities

Field	Value	IRS element (for citing)
BOY	15113621	BOY
EOY	13573560	EOY

Field	Value	IRS element (for citing)
Follow SFAS117	X	FollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	10772583	BOY
EOY	12246014	EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	11773926	BOY
EOY	13363548	EOY

Permanently Restricted Net Assets PermanentlyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	90000	BOY
EOY	90000	EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	22636509	BOY
EOY	25699562	EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	37750130	BOY
EOY	39273122	EOY

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	X	InfoInScheduleOPartXI
Reconcilation Revenue Expenses	2983329	ReconcilationRevenueExpenses
Reconcilation Other Changes	79724	ReconcilationOtherChanges
Method Of Accounting Accrual	X	MethodOfAccountingAccrual
Accountant Compile Or Review	0	AccountantCompileOrReview
FS Audited	1	FSAudited
Audit Committee	1	AuditCommittee
Financial Statement Separate	X	FinancialStatementSeparate
Federal Grant Audit Required	0	FederalGrantAuditRequired

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Publicly Supported Org170b1 Avi	X	PubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	20785323	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	19950796	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	21879337	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	18261062	CurrentTaxYearMinus1Year
Current Tax Year	22601859	CurrentTaxYear
Total	103478377	Total

Total170 Total170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	20785323	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	19950796	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	21879337	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	18261062	CurrentTaxYearMinus1Year
Current Tax Year	22601859	CurrentTaxYear
Total	103478377	Total

Field	Value	IRS element (for citing)
Public Support Total170	103478377	PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	1716212	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	1512451	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	1572008	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	1443239	CurrentTaxYearMinus1Year
Current Tax Year	1345423	CurrentTaxYear
Total	7589333	Total

Other Income170 OtherIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	14798	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	2303	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	1132	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	14	CurrentTaxYearMinus1Year
Current Tax Year	16	CurrentTaxYear
Total	18263	Total

Field	Value	IRS element (for citing)
Total Support	111085973	TotalSupport
Gross Receipts From Admissions Etc	25239	GrossReceiptsFromAdmissionsEtc
Public Support Pertcentage170	0.93150	PublicSupportPertcentage170
Public Support Pertcent Prior Year	0.92800	PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170	X	ThirtyThreePercntTestsCY170
General Explanation	Schedule A, Part II, Line 10, Explanation of Other Income: Other revenue	GeneralExplanation

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

Field	Value	IRS element (for citing)
Contributor Number	RESTRICTED	ContributorNumber

Contributor Name Business ContributorNameBusiness

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor Address US ContributorAddressUS

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Aggregate Contributions	RESTRICTED	AggregateContributions

Schedule D IRS990ScheduleD

Current Year CurrentYear

Field	Value	IRS element (for citing)
Beginning Of Year Balance	90000	BeginningOfYearBalance
Contributions	1312	Contributions
Other Expenditures	1312	OtherExpenditures
End Of Year Balance	90000	EndOfYearBalance

Current Year Minus1 Year CurrentYearMinus1Year

Field	Value	IRS element (for citing)
Beginning Of Year Balance	90000	BeginningOfYearBalance
Contributions	3792	Contributions
Other Expenditures	3792	OtherExpenditures
End Of Year Balance	90000	EndOfYearBalance

Current Year Minus2 Years CurrentYearMinus2Years

Field	Value	IRS element (for citing)
Beginning Of Year Balance	90000	BeginningOfYearBalance
Contributions	3715	Contributions
Other Expenditures	3715	OtherExpenditures
End Of Year Balance	90000	EndOfYearBalance

Current Year Minus3 Years CurrentYearMinus3Years

Field	Value	IRS element (for citing)
Beginning Of Year Balance	90000	BeginningOfYearBalance
Contributions	4009	Contributions
Other Expenditures	4009	OtherExpenditures
End Of Year Balance	90000	EndOfYearBalance

Field	Value	IRS element (for citing)
Permanent Endowment EOY Balance	1.00000	PermanentEndowmentEOYBalance
Endowments Held By Unrelated Orgs	1	EndowmentsHeldByUnrelatedOrgs
Endowments Held By Related Orgs	0	EndowmentsHeldByRelatedOrgs

Land Land

Field	Value	IRS element (for citing)
Investment Cost Or Other Basis	2800000	InvestmentCostOrOtherBasis
Other Cost Or Other Basis	1147363	OtherCostOrOtherBasis
Book Value	3947363	BookValue

Buildings Buildings

Field	Value	IRS element (for citing)
Investment Cost Or Other Basis	1629400	InvestmentCostOrOtherBasis
Other Cost Or Other Basis	4533166	OtherCostOrOtherBasis
Depreciation	1673477	Depreciation
Book Value	4489089	BookValue

Equipment Equipment

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	713350	OtherCostOrOtherBasis
Depreciation	453913	Depreciation
Book Value	259437	BookValue

Other Land Buildings OtherLandBuildings

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	189256	OtherCostOrOtherBasis
Depreciation	177210	Depreciation
Book Value	12046	BookValue

Field	Value	IRS element (for citing)
Total Of Book Value Land Buildings	8707935	TotalOfBookValueLandBuildings

Other Securities OtherSecurities

Field	Value	IRS element (for citing)
Description	Alternative investments - partnership	Description
Book Value	2230062	BookValue
Method Of Valuation	F	MethodOfValuation

Field	Value	IRS element (for citing)
Total Of Book Value Securities	2230062	TotalOfBookValueSecurities

Other Liabilities OtherLiabilities (3 entries)

DescriptionDescription	AmountAmount
Charitable gift annuities	$1,533,318
Rental deposits	$25,000
Capital lease obligations	$114,413

Field	Value	IRS element (for citing)
Total Of Amounts	1672731	TotalOfAmounts
Total Revenue	24410005	TotalRevenue
Total Expenses	21426676	TotalExpenses
Excess Or Deficit For Year	2983329	ExcessOrDeficitForYear
Net Unrealized GL On Investments	4614	NetUnrealizedGLOnInvestments
Other	$75,110	OtherAmount
Total Adjustments	79724	TotalAdjustments
Excess Or Deficit Per FS	3063053	ExcessOrDeficitPerFS
Tot Revenue Etc Audited Fincl Stmt	43465096	TotRevenueEtcAuditedFinclStmt
Net Unrealized Gains Investments	4614	NetUnrealizedGainsInvestments
Donated Srvc And Use Of Facilities	19045236	DonatedSrvcAndUseOfFacilities
Recoveries Of Prior Year Grants	99277	RecoveriesOfPriorYearGrants
Revenue Not Rptd F990	19149127	RevenueNotRptdF990
Revenue Subtotal	24315969	RevenueSubtotal
Investment Expenses Not Included	135815	InvestmentExpensesNotIncluded
Other Revenues Not Included	-41779	OtherRevenuesNotIncluded
Revenue Not Rptd On Fin Stmt	94036	RevenueNotRptdOnFinStmt
Total Revenue Per Form990	24410005	TotalRevenuePerForm990
Tot Expenses Etc Audited Fincl Stmt	40402043	TotExpensesEtcAuditedFinclStmt
Donated Services Use Of Facilities	19045236	DonatedServicesUseOfFacilities
Other Expenses Included	24167	OtherExpensesIncluded
Expenses Not Rptd F990	19069403	ExpensesNotRptdF990
Expenses Subtotal	21332640	ExpensesSubtotal
Investment Expenses Not Included2	135815	InvestmentExpensesNotIncluded2
Other Expenses Not Included	-41779	OtherExpensesNotIncluded
Expenses Not Rptd On Fin Stmt	94036	ExpensesNotRptdOnFinStmt
Total Expenses Per Form990	21426676	TotalExpensesPerForm990

Form990 Schedule D Part XIV Form990ScheduleDPartXIV (6 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Description of Intended Use of Endowment Funds:	Part V, Line 4:	The earnings on this endowment are available for the Alzheimer's Disease Research program and are recorded as temporarily restricted investment income and are released as spent.
Description of Uncertain Tax Positions Under FIN 48:	Part X:	AHAF has adopted the guidance under FASB ASC Topic 740, Income Taxes, related to accounting for uncertainty in income taxes. AHAF's management believes that AHAF has no material uncertain tax positions and, accordingly, it will not recognize any liability for unrecognized taxes.
Part XI, Line 8 - Other Adjustments:		Recoveries of prior year grants 99,277. Change in present value of grants -8,960. Special event net income -15,207. Total to Schedule D, Part XI, Line 8: 75,110.
Part XII, Line 4b - Other Adjustments:		Depreciation on rental property -41,779.
Part XIII, Line 2d - Other Adjustments:		Change in present value of grants 8,960. Special event net income 15,207.
Part XIII, Line 4b - Other Adjustments:		Depreciation on rental property -41,779.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	1	GrantRecordsMaintained

Accts Actvs Out US Table AcctsActvsOutUSTable

Field	Value	IRS element (for citing)
Region	Europe (Including Iceland & Greenland)	Region
Number Of Offices	0	NumberOfOffices
Number Of Employees	0	NumberOfEmployees
Type Of Activities Conducted	Grantmaking	TypeOfActivitiesConducted
Total Expenditures	100000	TotalExpenditures

Field	Value	IRS element (for citing)
Subtotal Number Of Offices	0	SubtotalNumberOfOffices
Subtotal Number Of Employees	0	SubtotalNumberOfEmployees
Cont Number Of Offices	0	ContNumberOfOffices
Cont Number Of Employees	0	ContNumberOfEmployees
Total Number Of Offices	0	TotalNumberOfOffices
Total Number Of Employees	0	TotalNumberOfEmployees
Subtotal Amount Spent	100000	SubtotalAmountSpent
Cont Amount Spent	0	ContAmountSpent
Total Amount Spent	100000	TotalAmountSpent

Grants To Orgs Outside US GrantsToOrgsOutsideUS

Field	Value	IRS element (for citing)
Region	Europe (Including Iceland & Greenland)	Region
Purpose Of Grant	National Glaucoma Research by Peter De Deyn, M.D., Ph.D. Entitled:(G2012028)	PurposeOfGrant
Amount Of Cash Grant	100000	AmountOfCashGrant
Manner Of Cash Disbursement	Wire transfer	MannerOfCashDisbursement

Field	Value	IRS element (for citing)
Total Number Of501c3 Orgs	1	TotalNumberOf501c3Orgs
Total Number Of Other Orgs	0	TotalNumberOfOtherOrgs
Transfer To Foreign Corp	1	TransferToForeignCorp
Interest In Foreign Trust	0	InterestInForeignTrust
Own Foreign Corp	0	OwnForeignCorp
Passive Foreign Invest Co	0	PassiveForeignInvestCo
Foreign Partnership	0	ForeignPartnership
Boycott Countries	0	BoycottCountries

Form990 Schedule F Part V Form990ScheduleFPartV

Field	Value	IRS element (for citing)
Identifier	Procedure for Monitoring Grants Outside the U.S.:	Identifier
Explanation	Schedule F, Part I, Line 2: AHAF interacts with all grantees at least quarterly by e-mail or at scientific meetings. In addition to these interactions, each grant recipient is required to submit separate detailed annual Scientific Progress and Financial Reports to AHAF. These are received by the AHAF Scientific Affairs department, and reviewed by scientific staff with broad expertise in molecular biology, cell biology, biochemistry, imaging and genetics. Senior staff reviews each Progress Report and evaluates the project for sufficient progress towards the specific aims proposed in the original application or any budgetary concerns. This effort is supported by additional scientific counsel from members of the AHAF Scientific Review Committees when required. In addition to statements of experimental progress, all grantees are asked to report any technical publications, media reports, or patent applications in which AHAF sponsored research is described. If significant concerns related to progress on the awards are discovered, the AHAF staff recommends appropriate actions to the Chair of the Board of Directors Grants Committee. The Scientific Affairs senior staff is empowered to authorize the withholding of funding, or discontinuation of awards, for any grantees that fail to achieve sufficient progress or fail to submit required reports. At the conclusion of the grant award period each grantee must complete and submit a Final Report that is also reviewed by the AHAF senior scientific staff. Evaluation of the work of each grantee is qualitatively and quantitatively assessed through various metrics related to impact of the grant on its targeted disease field. Such impact metrics have revealed that 95% of AHAF supported research results in research publications that advance the fields served by AHAF. This impact is further supported by the 2010 publication citation analysis that compared 1789 AHAF supported works to 3996 works supported by either the US Federal Government or that of other funding agencies. AHAF supported publications were cited nearly twice as frequently as the sample of papers published under the sole sponsorship of the US Government. With respect to a selection of manuscripts that listed solely non-US government funding sources, including other foundations, industry, and foreign governments, AHAF sponsored publications were cited, on average 2.3 times more frequently than the other funding sources. A final example of impact assessment revealed that the successes of AHAF grantees continue long after the grant expires. On average, each grantee receives 2.2 additional grants for projects spawned by the AHAF grant. These come at values nearly 10 times the level of the initial AHAF investment. AHAF solicits feedback from its grantees, and provides an anonymous forum for collecting such information. The Final Report package includes a page to be detached and anonymously mailed to the Scientific Affairs department. This document requests an assessment of the grantee experience as an AHAF awardee. Any suggestions, concerns, complaints, or positive experiences can be outlined and brought to the attention of AHAF on this form so that AHAF can address any areas needing improvement, reaffirm praise-worthy policies, or otherwise assess needs for programmatic change. The senior Scientific Staff present and summarize the status and progress on all grants to the AHAF Board of Directors at each of their quarterly Board Meetings.	Explanation

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	X	MailSolicitations
Email Solicitations	X	EmailSolicitations
Phone Solicitations	X	PhoneSolicitations
In Person Solicitations	X	InPersonSolicitations
Solicitation Of Non Govt Grants	X	SolicitationOfNonGovtGrants
Special Fundraising Events	X	SpecialFundraisingEvents
Agreement Ref Fundraising	1	AgreementRefFundraising

Fundraiser Activity Information FundraiserActivityInformation (2 entries)

Address Line1AddressUS/AddressLine1	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	ActivityActivity	Fundraiser Control Of FundsFundraiserControlOfFunds	Gross ReceiptsGrossReceipts	Amount Retained By ContractorAmountRetainedByContractor	Net To OrganizationNetToOrganization
WildeLW Robbins Associates Inc (Fundraising consultant)
201 Summer Street	Holliston	MA	01746	Direct Mail Fund. Counsel (June 2011 - March 2012)	0	12420984	873471	11547513
SCA Direct Inc (Fundraising consultant)
11208 Waples Mill Road Suite 106	Fairfax	VA	22030	Direct Mail Fund. Counsel (April - May 2011)	0	2073496	131250	1942246

Field	Value	IRS element (for citing)
Total Gross Receipts	14494480	TotalGrossReceipts
Total Retained By Contractors	1004721	TotalRetainedByContractors
Total Net To Organization	13489759	TotalNetToOrganization
Licensed States	AL	LicensedStates
Licensed States	AK	LicensedStates
Licensed States	AZ	LicensedStates
Licensed States	AR	LicensedStates
Licensed States	CA	LicensedStates
Licensed States	CO	LicensedStates
Licensed States	CT	LicensedStates
Licensed States	DC	LicensedStates
Licensed States	FL	LicensedStates
Licensed States	GA	LicensedStates
Licensed States	HI	LicensedStates
Licensed States	IL	LicensedStates
Licensed States	KS	LicensedStates
Licensed States	KY	LicensedStates
Licensed States	LA	LicensedStates
Licensed States	ME	LicensedStates
Licensed States	MD	LicensedStates
Licensed States	MA	LicensedStates
Licensed States	MI	LicensedStates
Licensed States	MN	LicensedStates
Licensed States	MS	LicensedStates
Licensed States	MO	LicensedStates
Licensed States	NH	LicensedStates
Licensed States	NJ	LicensedStates
Licensed States	NM	LicensedStates
Licensed States	NY	LicensedStates
Licensed States	NC	LicensedStates
Licensed States	ND	LicensedStates
Licensed States	OH	LicensedStates
Licensed States	OK	LicensedStates
Licensed States	OR	LicensedStates
Licensed States	PA	LicensedStates
Licensed States	RI	LicensedStates
Licensed States	SC	LicensedStates
Licensed States	TN	LicensedStates
Licensed States	UT	LicensedStates
Licensed States	VA	LicensedStates
Licensed States	WA	LicensedStates
Licensed States	WV	LicensedStates
Licensed States	WI	LicensedStates

Events Information EventsInformation

Field	Value	IRS element (for citing)
Name Of Event1	Golf Tournament	NameOfEvent1
Gross Receipts Event1	54504	GrossReceiptsEvent1
Charitable Contributions Event1	42845	CharitableContributionsEvent1
Gross Revenue Event1	11659	GrossRevenueEvent1
Cash Prizes Event1	565	CashPrizesEvent1
Non Cash Prizes Event1	2651	NonCashPrizesEvent1
Rent Facility Costs Event1	9299	RentFacilityCostsEvent1
Food And Beverage Event1	5302	FoodAndBeverageEvent1
Entertainment Event1	0	EntertainmentEvent1
Other Direct Expenses Event1	9049	OtherDirectExpensesEvent1
Gross Receipts Total	54504	GrossReceiptsTotal
Charitable Contributions Total	42845	CharitableContributionsTotal
Gross Revenue Total Events	11659	GrossRevenueTotalEvents
Cash Prizes Total Events	565	CashPrizesTotalEvents
Non Cash Prizes Total Events	2651	NonCashPrizesTotalEvents
Rent Facility Costs Total Events	9299	RentFacilityCostsTotalEvents
Food And Beverage Total Events	5302	FoodAndBeverageTotalEvents
Other Direct Expenses Total Events	9049	OtherDirectExpensesTotalEvents
Direct Expense Summary Events	26866	DirectExpenseSummaryEvents
Net Income Summary	-15207	NetIncomeSummary

Form990 Schedule G Part IV Form990ScheduleGPartIV

Field	Value	IRS element (for citing)
Identifier	Explanation of Fundraising Payments	Identifier
Return Reference	Schedule G, Part I, Line 2b, Column (v)	ReturnReference
Explanation	In the contracts with SCA Direct, Inc. and Wilde/LW Robbins Associates, Inc., the management fees are a fixed amount per month for in scope fundraising consulting services. Work performed out of the scope of fundraising consulting services are approved by AHAF before they are paid and performed.	Explanation

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Records Maintained	1	RecordsMaintained

Recipient Table RecipientTable (42 entries)

Address Line1AddressUS/AddressLine1	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	EIN Of RecipientEINOfRecipient	IRC SectionIRCSection	Amount Of Cash GrantAmountOfCashGrant	Purpose Of GrantPurposeOfGrant
Northwestern University
300 East Superior Street	Chicago	IL	60611	362167817	501(C)(3)	300000	Alzheimer's Disease Reasearch by Robert Vassar, Ph.D. Entitled: (A2012063)
Stanford University
300 Pasteur Drive	Stanford	CA	94305	941156365	501(C)(3)	100000	Alzheimer's Disease Reasearch by Alya Raphael, Ph.D. Entitled: (A2012648)
The J David Gladstone Institutes
1650 Owens Street	San Francisco	CA	94158	237203666	501(C)(3)	100000	Alzheimer's Disease Reasearch by Hwajin Kim, Ph.D. Entitled: (A2012629)
Washington University
660 South Euclid Avenue	St Louis	MO	63110	430653611	501(C)(3)	150000	Alzheimer's Disease Reasearch by Carl Frieden, Ph.D. Entitled: (A2012422)
Washington University
660 South Euclid Avenue	St Louis	MO	63110	430653611	501(C)(3)	150000	Alzheimer's Disease Reasearch by Jungsu Kim, Ph.D. Entitled: (A2012421)
The University of Chicago
924 East 57th Street JFK-RO14	Chicago	IL	60637	362177139	501(C)(3)	150000	Alzheimer's Disease Reasearch by Angele Parent, Ph.D. Entitled: (A2012386)
Washington University
660 South Euclid Avenue	St Louis	MO	63110	430653611	501(C)(3)	300000	Alzheimer's Disease Reasearch by John Cirrito, Ph.D. Entitled: (A2012151)
University of North Dakota School of Medicine
504 Hamline Street	Grand Forks	ND	58203	456014235	501(C)(3)	200000	Alzheimer's Disease Reasearch by Colin Combs, Ph.D. Entitled: (A2012115)
The Regents of the University of Michigan
210 Washtenaw Avenue	Ann Arbor	MI	48109	386006309	501(C)(3)	150000	Alzheimer's Disease Reasearch by Jason E. Gestwicki, Ph.D. Entitled: (A2012078)
Columbia University
630 West 168th Street	New York	NY	10032	135598093	501(C)(3)	50000	Alzheimer's Disease Reasearch by Ismael Santa-Maria Perez, Ph.D. Entitled: (A2012636)
Columbia University
630 West 168th Street	New York	NY	10032	135598093	501(C)(3)	100000	Alzheimer's Disease Reasearch by Jessica Wu, Ph.D. Entitled: (A2012635)
Mount Sinai School of Medicine
One Gustave L Levy Place	New York	NY	10029	136171197	501(C)(3)	100000	Alzheimer's Disease Reasearch by Soong Ho Kim, Ph.D. Entitled: (A2012625)
Massachusetts General Hospital
149 13th Street	Charlestown	MA	021292020	041564655	501(C)(3)	100000	Alzheimer's Disease Reasearch by Ksenia Kastanenka, Ph.D. Entitled: (A2012624)
Harvard University
240 Longwood Avenue	Boston	MA	02115	042103580	501(C)(3)	50000	Alzheimer's Disease Reasearch by Sonia Mazzitelli, Ph.D. Entitled: (A2012608)
Massachusetts General Hospital
149 13th Street	Charlestown	MA	021292020	041564655	501(C)(3)	148962	Alzheimer's Disease Reasearch by Mert Sabuncu, Ph.D. Entitled: (A2012333)
University of Pennsylvania
3615 Chestnut Street	Philadelphia	PA	191042676	231352685	501(C)(3)	300000	Alzheimer's Disease Reasearch by Steven Arnold, M.D. Entitled: (A2012116)
Rutgers University
604 Allison Road	Piscataway	NJ	08854	226001086	501(C)(3)	300000	Alzheimer's Disease Reasearch by Karl Herrup, Ph.D. Entitled: (A2012101)
Johns Hopkins University
400 North Broadway Avenue	Baltimore	MD	21205	520595110	501(C)(3)	150000	Alzheimer's Disease Reasearch by Seth Margolis, Ph.D. Entitled: (A2012070)
Columbia University
630 West 168th Street	New York	NY	10032	135598093	501(C)(3)	300000	Alzheimer's Disease Reasearch by W. Haung (Ho) Yu, Ph.D. Entitled:(A2012057)
Columbia University
630 West 168th Street	New York	NY	10032	135598093	501(C)(3)	150000	Alzheimer's Disease Reasearch by Tae-Wan Kim, Ph.D. Entitled:(A2012056)
Trustees of Boston University
72 East Concord Street	Boston	MA	02118	042103547	501(C)(3)	150000	Alzheimer's Disease Reasearch by Benjamin Wolozin, M.D., Ph.D. Entitled: (A2012054)
Brigham and Women's Hospital
77 Louis Pasteur Avenue	Boston	MA	02115	042312909	501(C)(3)	100000	Alzheimer's Disease Reasearch by Mel Feany, M.D., Ph.D. Entitled:(A2012029)
Trustees of Indiana University
723 West Michigan Street	Indianapolis	IN	46202	356001673	501(C)(3)	100000	National Glaucoma Research by Jason Meyer, Ph.D. Entitled:(G2012027)
Board of Regents of the University of Wisconsin System
600 Highland Avenue	Madison	WI	537924673	396006492	501(C)(3)	100000	National Glaucoma Research by Leonard Levin, M.D., Ph.D. Entitled: (G2012015)
Johns Hopkins University
400 North Broadway Avenue	Baltimore	MD	21287	520595110	501(C)(3)	100000	National Glaucoma Research by Derek Welsbie, M.D., Ph.D. Entitled: (G2012034)
Johns Hopkins University
400 North Broadway Avenue	Baltimore	MD	21287	520595110	501(C)(3)	100000	National Glaucoma Research by Shannath Merbs, M.D., Ph.D. Entitled: (G2012033)
Johns Hopkins University
400 North Broadway Avenue	Baltimore	MD	21287	520595110	501(C)(3)	100000	National Glaucoma Research by Zhiyong Yang, M.D., Ph.D. Entitled: (G2012032)
University of South Florida
4001 E Fletcher Avenue	Tampa	FL	33613	593102112	501(C)(3)	100000	National Glaucoma Research by Chad Anthony Dickey, Ph.D. Entitled:(G2012071)
Georgetown University
3700 Reservoir Road NW	Washington	DC	200571107	530196603	501(C)(3)	100000	National Glaucoma Research by Alexander Theos, Ph.D. Entitled: (G2012025)
Duke University Department of Opthalmology
2351 Erwin Road	Durham	NC	27710	560532129	501(C)(3)	100000	National Glaucoma Research by Paloma B. Liton, Ph.D. Entitled: (G2012022)
Mayo Clinic Jacksonville
4500 San Pablo Road South	Jacksonville	FL	32224	593337028	501(C)(3)	100000	National Glaucoma Research by Wing Lee, Ph.D. Entitled: (G2012011)
Vanderbilt University Medical Center
2311 Pierce Avenue	Nashville	TN	372328808	620476822	501(C)(3)	100000	National Glaucoma Research by John Kuchtey, Ph.D. Entitled: (G2012007)
University of Oklahoma Health Sciences Center
941 Stanton L Young Boulevard	Oklahoma Cty	OK	73104	736017987	501(C)(3)	100000	Macular Degeneration Research by Krysten Farjo, Ph.D. Entitled: (M2012057)
University of Texas Medical Branch
700 University Boulevard	Galveston	TX	77555	746000949	501(C)(3)	100000	Macular Degeneration Research by Jiyang Cai, Ph.D., Ph.D. Entitled:(M2012012)
Johns Hopkins University
400 North Broadway Avenue	Baltimore	MD	212312128	520595110	501(C)(3)	100000	Macular Degeneration Research by Noriko Esumi, M.D., Ph.D. Entitled: (M2012102)
Albert Einstein College of Medicine
1300 Morris Park Avenue	Bronx	NY	10461	131624225	501(C)(3)	100000	Macular Degeneration Research by Wei Liu, Ph.D. Entitled: (M2012044)
Trustees of Boston University
72 East Concord Street	Boston	MA	02118	042103547	501(C)(3)	100000	Macular Degeneration Research by Matthew Nugent, Ph.D. Entitled: (M2012014)
Vanderbilt University Medical Center
2311 Pierce Avenue	Nashville	TN	372328808	620476822	501(C)(3)	100000	Macular Degeneration Research by Ashwath Jayagopal, Ph.D. Entitled: (M2012067)
University of Miami
1638 NW 10th Avenue	Miami	FL	33136	590624458	501(C)(3)	100000	Macular Degeneration Research by Gaofeng Wang, Ph.D. Entitled: (M2012048)
Vanderbilt University Medical Center
2213 Garland Avenue	Nashville	TN	372328808	620476822	501(C)(3)	100000	Macular Degeneration Research by Milam Brantley, M.D., Ph.D. Entitled: (M2012045)
University of Florida
1600 SW Archer Road	Gainesville	FL	32610	596002052	501(C)(3)	100000	Macular Degeneration Research by Haoyu Mao, Ph.D. Entitled: (M2012029)
University of Miami
1638 NW 10th Avenue	Miami	FL	33136	590624458	501(C)(3)	100000	Macular Degeneration Research by Wei Li, Ph.D. Entitled: (M2012026)

Field	Value	IRS element (for citing)
Total Nbr Of501 C3 And Govt Grants	28	TotalNbrOf501C3AndGovtGrants
Total Nbr Of Other Organizations	0	TotalNbrOfOtherOrganizations

Form990 Schedule I Part IV Form990ScheduleIPartIV

Field	Value	IRS element (for citing)
Identifier	Procedure for Monitoring Grants in the U.S.:	Identifier
Return Reference	Part I, Line 2:	ReturnReference
Explanation	Schedule I, Part I, Line 2: AHAF interacts with all grantees at least quarterly by e-mail or at scientific meetings. In addition to these interactions, each grant recipient is required to submit separate detailed annual Scientific Progress and Financial Reports to AHAF. These are received by the AHAF Scientific Affairs department, and reviewed by scientific staff with broad expertise in molecular biology, cell biology, biochemistry, imaging and genetics. Senior staff reviews each Progress Report and evaluates the project for sufficient progress towards the specific aims proposed in the original application or any budgetary concerns. This effort is supported by additional scientific counsel from members of the AHAF Scientific Review Committees when required. In addition to statements of experimental progress, all grantees are asked to report any technical publications, media reports, or patent applications in which AHAF sponsored research is described. If significant concerns related to progress on the awards are discovered, the AHAF staff recommends appropriate actions to the Chair of the Board of Directors Grants Committee. The Scientific Affairs senior staff is empowered to authorize the withholding of funding, or discontinuations of awards, for any grantees that fail to achieve sufficient progress or fail to submit required reports. At the conclusion of the grant award period, each grantee must complete and submit a Final Report that is also reviewed by the AHAF senior scientific staff. Evaluation of the work of each grantee is qualitatively and quantitatively assessed through various metrics related to impact of the grant on its targeted disease field. Such impact metrics have revealed that 95% of AHAF supported research results in research publications that advance the fields served by AHAF. This impact is further supported by the 2010 publication citation analysis that compared 1789 AHAF supported works to 3996 works supported by either the US Federal Government or that of other funding agencies. AHAF supported publications were cited nearly twice as frequently as the sample of papers published under the sole sponsorship of the US Government. With respect to a selection of manuscripts that listed solely non-US government funding sources, including other foundations, industry, and foreign governments, AHAF sponsored publications were cited, on average 2.3 times more frequently than the other funding sources. A final example of impact assessment revealed that the successes of AHAF grantees continue long after the grant expires. On average, each grantee receives 2.2 additional grants for projects spawned by the AHAF grant. These come at values nearly 10 times the level of the initial AHAF investment. AHAF solicits feedback from its grantees, and provides an anonymous forum for collecting such information. The Final Report package includes a page to be detached and anonymously mailed to the Scientific Affairs department. This document requests an assessment of the grantee experience as an AHAF awardee. Any suggestions, concerns, complaints, or positive experiences can be outlined and brought to the attention of AHAF on this form so that AHAF can address any areas needing improvement, reaffirm praise-worthy policies, or otherwise assess needs for programmatic change. The senior Scientific Staff present and summarize the status and progress on all grants to the AHAF Board of Directors at each of their quarterly Board Meetings.	Explanation

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	X	CompensationCommittee
Independent Consultant	X	IndependentConsultant
Form990 Of Other Organizations	X	Form990OfOtherOrganizations
Compensation Survey	X	CompensationSurvey
Board Or Committee Approval	X	BoardOrCommitteeApproval
Severance Payment	0	SeverancePayment
Supplemental Nonqual Retire Plan	0	SupplementalNonqualRetirePlan
Equity Based Comp Arrangement	0	EquityBasedCompArrangement
Comp Based On Revenue Of Filing Org	0	CompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related Orgs	0	CompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing Org	0	CompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate Orgs	0	CompBasedNetEarningsRelateOrgs
Any Non Fixed Payments	1	AnyNonFixedPayments
Initial Contract Exception	0	InitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (5 entries)

Base Compensation Filing OrgBaseCompensationFilingOrg	Comp Based On Related OrgsCompBasedOnRelatedOrgs	Bonus Filing OrgBonusFilingOrg	Bonus Related OrgsBonusRelatedOrgs	Other Compensation Filing OrgOtherCompensationFilingOrg	Other Compensation Related OrgsOtherCompensationRelatedOrgs	Deferred Comp Filing OrgDeferredCompFilingOrg	Deferred Comp Related OrgsDeferredCompRelatedOrgs	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg	Nontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgs	Total Compensation Filing OrgTotalCompensationFilingOrg	Total Compensation Related OrgsTotalCompensationRelatedOrgs	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrg	Comp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs
Stacy Pagos Haller
239604	0	45000	0	818	0	12250	0	40176	0	337848	0	0	0
Donna Callison
161000	0	0	0	1032	0	6125	0	18669	0	186826	0	0	0
Guy Eakin Ph D
120420	0	0	0	216	0	18734	0	26588	0	165958	0	0	0
David F Marks CPA CMA
145507	0	0	0	552	0	22150	0	17134	0	185343	0	0	0
Melissa May
133540	0	0	0	552	0	568	0	15982	0	150642	0	0	0

Form990 Schedule J Part III Form990ScheduleJPartIII (2 entries)

Return ReferenceReturnReference

ExplanationExplanation

Part I, Line 3

Before approving the compensation of the CEO, the Board determines the total compensation to be provided by AHAF to the CEO is reasonable in light of the position, responsibility and qualification of the position held including the result of an evaluation of prior performance for the Foundation, if applicable. The CEO is evaluated annually by the Board through the use of an in-depth goal attainment structure, (developed with advice from Board Source) that includes a self assessment and Board assessment and evaluation against set goals, outcomes and deliverables. The Board obtains and considers appropriate data, including a salary survey, which includes information compiled from the Form 990 of other organizations, concerning compensation paid to CEOs in like circumstances. In making the determination, the Board shall consider total compensation to include the salary and value of all benefits provided by AHAF to the individual in payment for services. At the time of the AHAF Board discussion and decision concerning the CEOs compensation, the CEO is not present in the meeting.

Part I, Line 7

As the President/CEO's bonus was not a fixed payment specified in her employment contract, this item has been answered 'yes' in accordance with the Internal Revenue Service's instructions. However, it should be noted that her bonus was a non-fixed payment based on AHAF's internal procedures. The Board of Directors considers the award of a discretionary bonus each year. The determination of the bonus compensation is capped at $50,000 and if not warranted will not be awarded at all. The determination is made by the full Board upon recommendation of its Compensation Committee. The Committee considers a set of goals for the organization developed at the beginning of the year in consultation with the President/CEO. Each goal is evaluated at the end of the fiscal year to determine whether the goal has been met or exceeded. A value is ascribed to goals which are met or exceeded, with exceed or "reach" goals receiving a higher value and unmet goals receiving no value. The value of all met or exceeded goals is then added together and inserted as the numerator in an equation with the total cap of the bonus as the denominator. This equation is then used to calculate the fraction or percentage, if any, of the total allowable bonus which will be awarded.

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTraded

Field	Value	IRS element (for citing)
Non Cash Checkbox	X	NonCashCheckbox
Number Of Contributions	11	NumberOfContributions
Noncash Contribs Rptd F990	46743	NoncashContribsRptdF990
Method Of Determining Revenues	FMV	MethodOfDeterminingRevenues

Other Non Cash Contributions Table OtherNonCashContributionsTable (2 entries)

Non Cash CheckboxNonCashCheckbox	DescriptionDescription	Number Of ContributionsNumberOfContributions	Noncash Contribs Rptd F990NoncashContribsRptdF990	Method Of Determining RevenuesMethodOfDeterminingRevenues
X	Donated Food	1	2800	FMV
X	Special events items	1	7249	FMV

Field	Value	IRS element (for citing)
Any Property That Must Be Held	0	AnyPropertyThatMustBeHeld
Review Process Unusual NC Gifts	1	ReviewProcessUnusualNCGifts
Third Parties Used	0	ThirdPartiesUsed

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (21 entries)

Return ReferenceReturnReference	ExplanationExplanation	IdentifierIdentifier
Form 990, Part VI, Section A, line 4	Effective January 1, 2012, AHAF's Bylaws have been amended to conform to the governance over nonprofit organization per the new D.C. Nonprofit Corporation Act of 2010. These changes are listed below. Article IV 1. Providing the Board with the power to establish committees. 2. The Chairperson recommends the members and Chair of these committees. 3. The composition of the Board and committees has been defined. Article V 1. Prohibiting the filling of vacancies. Article XI 1. Limits the contracting of loans without approval of the Board.
Form 990, Part VI, Section B, line 11	A draft of the federal Form 990 shall be distributed to the Audit Committee for review prior to being submitted to the Internal Revenue Service. The draft federal Form 990 shall be distributed early enough to provide each Committee member with a reasonable amount of time for review and submission of questions or comments prior to the filing deadline. The final federal Form 990 shall be distributed to each Board member prior to being filed with the Internal Revenue Service. The draft and final Form 990 may be distributed in person, by regular mail, e-mail, or fax.
Form 990, Part VI, Section B, line 12c	AHAF has all employees, officers, and directors agree to the code of conduct that includes adherence to the Conflict of Interest and Implementation Policy. Each board director, officer, and employee is required annually to complete a conflict of interest disclosure statement, which is thereafter reviewed by AHAF's chief compliance officer. If a conflict is reported it is then referred to AHAF's legal counsel and, if appropriate and necessary, then to the Board of Directors or its appointed Committee for further action. Although a person with a potential or actual conflict may provide factual information to the Board and respond to the Board's questions, he or she may not participate in the discussion or decision of a proposed transaction or matter. The conflicted person shall recuse him/herself from the deliberation process, and leave the meeting.
Form 990, Part VI, Section B, line 15a	AHAF's Board of Directors has overall authority and responsibility for approving the annual budget which includes compensation for all employees at every level including non-director officers. All pay adjustments are made on a yearly basis effective April 1st, the beginning of the AHAF fiscal year. Before approving the compensation of the CEO, the Board of Directors determines the total compensation to be provided by AHAF to the CEO is reasonable in light of the position, responsibility and qualification of the position held including the result of an evaluation of prior performance for AHAF, if applicable. The CEO is evaluated annually by the Board of Directors through the use of an in-depth goal attainment structure, (developed with advice from Board Source) that includes a self assessment and a Board of Directors assessment and evaluation against set goals, outcomes and deliverables. The Board of Directors obtains and considers appropriate data, including a salary survey, which includes information compiled from the federal Form 990 of other organizations, concerning compensation paid to CEOs in like circumstances. In making the determination, the Board of Directors shall consider total compensation to include the salary and value of all benefits provided by AHAF to the individual in payment for services. At the time of the AHAF Board discussion and decision concerning the CEOs compensation, the CEO is not present in the meeting. The Board of Directors shall set forth the basis for its decisions with respect to compensation in the minutes of the meeting at which the decisions are made, including the conclusions of the evaluation and the basis for determining that the individual's compensation was reasonable in light of the evaluation and comparability data.
Form 990, Part VI, Section C, line 19	AHAF makes its governing documents including its articles of incorporation and bylaws, conflict of interest policy, audited financial statements and federal Form 990 available to the public upon request. In addition, the public also has access to the annual report, the federal Form 1023, audited financial statements, the 501(C)(3) letter of determination from the Internal Revenue Service, and federal Form 990 on the AHAF website.
Form 990, Part XI, line 5:	Net unrealized gains on investments: 4,614. Recoveries of prior year grants 99,277. Change in Present value of grants -8,960. Special event net income -15,207. Total to Form 990, Part XI, Line 5: 79,724.	Changes in Net Assets or Fund Balances:
	Schedule I, Part II, Line 1, Column (H): Name of organization or government: Northwestern University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Robert Vassar, Ph.D. Entitled: (A2012063) BACE1 and Axon Guidance. Investigator's Summary: Pharmaceutical companies are developing drugs to block the enzyme BACE1 that makes the toxic substance amyloid that accumulates in the brains of Alzheimer's disease patients. However, our results suggest that these drugs may disturb the wiring of the brain and therefore may cause negative side-effects, such as problems with learning and memory. The goal of our research is to better understand the role of BACE1 in processes involved in brain wiring and then inform drug makers and physicians as to the potential for BACE1 drug side-effects and how to avoid them. Name of organization or government: Stanford University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Alya Raphael, Ph.D. Entitled: (A2012648) Stress Granule Pathways in TDP-43 Toxicity. Investigator's Summary: Alzheimer's disease and related neurodegenerative disease are devastating diseases that many thousands of people each year and have enormous societal costs. The pathology of many of these diseases involves the formation of insoluble protein aggregates, although whether these aggregates are the cause or result of disease is unknown. TDP-43 and the related protein FUS are found aggregated in several neurodegenerative diseases and understanding the biology behind their pathology may point to new treatment strategies. Name of organization or government: The J. David Gladstone Institutes. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Hwajin Kim, Ph.D. Entitled: (A2012629) Mitochondrial fission at the synapse in Alzheimer's Disease. Investigator's Summary: Mitochondria are vital organelles that generate energy, and fragmentation of mitochondria appears to play an important role in the pathogenesis of Alzheimer's disease (AD). In this proposal, we study the mechanisms by which mitochondrial fission may contribute to AD, and test whether reversal of mitochondrial fission may be an effective therapeutic strategy for preventing AD progression.
	Name of organization or government: Washington University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Carl Frieden, Ph.D. Entitled: (A2012422) Develop Screening Assays to Differentiate ApoE Isoforms. Investigator's Summary: The primary cause for developing late-onset Alzheimer's Disease rests in the properties of one of the apoE isoforms, specifically apoE4. The screening procedures we will develop are designed to lead to the long term goal of finding therapeutic agents that specifically target apoE4 without disrupting the physiological function of the normal apoE3 isoform. Our hypothesis is that such agents will alter the deleterious effects of apoE4 and thereby delay or prevent the onset of Alzheimer's Disease. Name of organization or government: Washington University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Jungsu Kim, Ph.D. Entitled: (A2012421) Role of a LDLR-interacting protein in LDLR, ApoE, and Abeta Metabolism. Investigator's Summary: Apolipoprotein E (ApoE) genotype is the strongest genetic risk factor for Alzheimer's disease (AD). Our previous studies suggest that low density lipoprotein receptor (LDLR) binds to apoE protein and dramatically affects AD pathogenesis. We propose to investigate role of a novel LDLR interacting protein in regulating LDLR and apoE protein levels in order to test its potential as AD therapeutics. Name of organization or government: The University of Chicago. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Angele Parent, Ph.D. Entitled: (A2012386) Functional Interaction of APP-CTF with GalphaS in Brain. Investigator's Summary: Our research efforts focus on understanding the molecular and cellular mechanisms associated with Alzheimer's disease (AD) pathogenesis. In this proposal, we intend to use mice to study the function of proteins that are suspected to contribute to the pathogenesis in this disease. We use cell culture and transgenic mouse models in our research to clarify the role of genetically engineer proteins (such as our membrane-tethered amyloid intracellular domain), which could affect the progression of AD. AAV brain administration strategy in AD mouse models is the first step toward a comprehensive evaluation of the beneficial effect associated with brain overexpression of these modified proteins. Our ultimate goal is to develop novel therapeutic strategies applicable to human to fight this devastating disorder.
	Name of organization or government: Washington University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by John Cirrito, Ph.D. Entitled: (A2012151) Endocytic Trafficking in Synaptic Amyloid-B Generation. Investigator's Summary: Amyloid-beta peptide aggregation and accumulation appears to be the initial step that sets off a cascade of factors that lead to Alzheimer's disease (AD). Two proteins, PICALM and Bin1, have recently been identified in genetic studies as risk factors for AD. This proposal will determine the cellular mechanisms by which these proteins act and interact to mediate amyloid-beta generation in living mice. Name of organization or government: University of North Dakota School of Medicine. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Colin Combs, Ph.D. Entitled: (A2012115) Novel Approach for Attenuating Microgliosis in Alzheimer's Disease. Investigator's Summary: The main goal of this project is to prove that a specific protein is responsible for most of the inflammation that occurs in the brain during Alzheimer's disease. We intend to not only identify this protein but also test specific strategies to interfere with its function using a mouse model of the disease. This interference should be able to decrease the inflammation in the brain and decrease behavioral decline. Name of organization or government: The Regents of the University of Michigan. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Jason E. Gestwicki, Ph.D. Entitled: (A2012078) Chemical Approaches to Reducing Tau Levels. Investigator's Summary: Tau is a protein that aberrantly accumulates in the brains of patients with Alzheimer's disease. The goal of this proposal is to determine whether newly discovered chemical inhibitors of heat shock protein 70 (Hsp70) will reduce tau accumulation. Such compounds would be expected to be potential therapeutics with an under-explored mechanism.
	Name of organization or government: Columbia University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Ismael Santa-Maria Perez, Ph.D. Entitled: (A2012636) Role of MicroRNAs in Tangle Predominant Alzheimer's Disease. Investigator's Summary: Neurofibrillary Tangles are histopathological hallmarks of Alzheimer's disease. The lack of a defined mechanism of Neurofibrillary Tangle formation is impeding the development of new therapies. Determining the mechanism of tau accumulation uncovering genetics variants, or deciphering a dysregulation in microRNAs MAPT gene expression regulation will let allow us to propose different targets suitable for therapy of this variant of Alzheimer's disease. Name of organization or government: Columbia University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Jessica Wu, Ph.D. Entitled: (A2012635) Conformation-Dependent Uptake and Secretion of Tau. Investigator's Summary: The tau protein is important to maintain neuronal health in the central nervous system and subsequently, when misfolded, accumulates and becomes a key pathological feature in Alzheimer's disease and other frontotemporal dementia. We have determined that misfolded tau is taken up in neurons. This project aims to identify the important questions of how misfolded tau is released from neurons and then taken up by surrounding neurons to spread pathology in diseases. Name of organization or government: Mount Sinai School of Medicine. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Soong Ho Kim, Ph.D. Entitled: (A2012625) Testing of Group II mGluR Antagonist as a Potential Alzheimer's Disease Treatment. Investigator's Summary: We will test a drug candidate that can potentially reduce brain levels of amyloid beta protein, which has been shown to be toxic to brain cells. This drug has also been shown to enhance brain function, act as an anti-depressant and anti-anxiety medication and also has potential to encourage the brain to replace damaged cells involved in learning and memory.
	Name of organization or government: Massachusetts General Hospital. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Ksenia Kastanenka, Ph.D. Entitled: (A2012624) Role of Neural Activity in Alzheimer's Disease. Investigator's Summary: Development of therapeutics for Alzheimer's disease (AD) has been hampered by a lack of clear understanding of its etiology. Until recently scientific community has been focusing solely on the molecular mechanisms leading to the onset of AD, disregarding perturbations of neural activity within the brain networks vulnerable to AD pathology. This research will provide great insight into the area of neural activity that has been greatly unexplored and will build a stronger platform for innovation of successful therapeutic agents. Name of organization or government: Harvard University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Sonia Mazzitelli, Ph.D. Entitled: (A2012608) Mechanism of RIP-1 in Mediating Abeta Neurotoxicity. Investigator's Summary: Chronic inflammation is associated with broad spectrum of neurodegenerative diseases of aging including Alzheimer's disease (AD). We propose a novel way to investigate the connection between chronic inflammation and neuronal loss associated with AD. This research will provide relevant information to propose: 1- a new target for the treatment of AD; 2- the potential of developing a new therapy. Name of organization or government: Massachusetts General Hospital. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Mert Sabuncu, Ph.D. Entitled: (A2012333) Predicting Future Alzheimer's Disease Onset Based on MRI and Genotype. Investigator's Summary: Alzheimer's disease, the most common form of dementia, has a multi-year pre-clinical phase, during which subtle changes begin to happen in the brain, yet clinical symptoms such as memory loss don't yet appear. This project will develop a computer system that analyzes brain Magnetic Resonance Imaging (MRI) and saliva-derived DNA data in order to reliably quantify risk of Alzheimer's before memory complaints begin. This technology will provide a means to identify high-risk but healthy individuals who would benefit most from a drug that can slow down the progression of the disease.
	Name of organization or government: University of Pennsylvania. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Steven Arnold, M.D. Entitled: (A2012116) Effect of Insulin Sensitizer Metformin on Alzheimer's Disease Biomarkers. Investigator's Summary: Previous studies and our own laboratory work have shown that the brain in Alzheimer's disease (AD) is resistant to the healthy growth effects of insulin and that re-sensitizing brain cells to insulin may be a useful therapeutic strategy. We have identified the anti-diabetes drug, metformin, as a safe medicine that enters the brain and re-sensitizes insulin receptors. This proposal seeks to conduct an efficient clinical trial with metformin in people with mild cognitive impairment and early dementia due to AD to determine its effect on cognitive functioning and physiological and biochemical biomarkers of AD. Name of organization or government: Rutgers University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Karl Herrup, Ph.D. Entitled: (A2012101) Glutamine as a Neuroprotective Agent in Alzheimer's Disease Therapy. Investigator's Summary: Glutamine is a simple amino acid that has been clinical proven to provide tissue protection under the stress of chemo- or radiation therapy as well as after intestinal surgery. Strangely, this effect has never been studied to any degree in the nervous system to determine if neurons can be similarly protected from neurodegeneration, as in Alzheimer's disease. We have developed preliminary data to show that this is likely and we propose a series of experiments both in tissue culture and in mouse models to move this idea as rapidly as possible towards its application in human beings. Name of organization or government: Johns Hopkins University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Seth Margolis, Ph.D. Entitled: (A2012070) Correcting Synapse Loss in the Alzheimer's Disease Brain. Investigator's Summary: Several recent studies including our own suggest the intriguing hypothesis that neurodegenerative disorders such as Alzheimer's disease (AD) share a common causative feature: loss of appropriate numbers of functional connections in the brain. We have identified an endogenous biological inhibitor of brain development, which is increased in amount in the AD brain. This project is aimed at discovering the AD phenotypes which are a result of this increased inhibitor amount, and identifying small molecule blockers to this inhibitor; a first step in a larger project to develop therapeutics for treating AD.
	Name of organization or government: Columbia University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by W. Haung (Ho) Yu, Ph.D. Entitled: (A2012057) Tau Homeostasis Via Proteasomal and Autophagic Activity. Investigator's Summary: This grant will further our understanding of how the ubiquitin-proteasome (UPS)and autophagic-lysosome system (A-LS) act in concert to maintain protein homeostasis. In Alzheimer's disease, protein aggregation is a hallmark which is often accompanied by failure of UPS and A-LS, suggesting that these two degradation pathways are important for disease prevention. Along with our understanding of these two mechanism, this study will provide insight into the utility of compounds that enhance UPS and A-LS function in reducing tauopathy and restoring long-lived UPS and A-LS activity. Name of organization or government: Columbia University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Tae-Wan Kim, Ph.D. Entitled: (A2012056) Novel CNS Transporter Target in Alzheimer's Disease. Investigator's Summary: We have identified novel therapeutic target in Alzheimer's disease. The proposed research will further validate the new target and generate therapeutic lead compound. Furthermore, we will study this target further using cell biological approach. Name of organization or government: Trustees of Boston University. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Benjamin Wolozin, M.D., Ph.D. Entitled: (A2012054) RNA Binding Proteins in Alzheimer's Disease. Investigator's Summary: RNA binding proteins (RBPs) regulate the conversion of messenger RNA to protein through formation of complexes, termed RNA granules. Stress induces formation of a particular type of complex, termed the stress granules (SG). By examining SGs, we have identified novel types of pathology in the brains of subjects with Alzheimer's disease, and in this proposal we will investigate how these SGs might contribute to the causes and diagnosis of Alzheimer's disease.
	Name of organization or government: Brigham and Women's Hospital. Purpose of Grant or Assistance: Alzheimer's Disease Reasearch by Mel Feany, M.D., Ph.D. Entitled: (A2012029) Mitochondrial Pathology in Tauopathy. Investigator's Summary: In our proposal we use clues from genetic screens to develop a detailed understanding of the mechanisms by which tau becomes toxic to neurons in Alzheimer's disease and related tauopathies. In particular, we test the hypothesis that abnormal stabilization of F-actin by tau results in mislocalization of Drp1, mitochondrial elongation, and subsequent mitochondrial dysfunction. If we can confirm our preliminary data supporting our hypothesis, then the wide array of well-characterized proteins that control the stability of the actin cytoskeleton, mitochondrial dynamics, and mitochondrial function will become attractive as potential therapeutic targets in Alzheimer's disease and related tauopathies. Name of organization or government: Trustees of Indiana University. Purpose of Grant or Assistance: National Glaucoma Research by Jason Meyer, Ph.D. Entitled: (G2012027) Patient-specific Stem Cells for Studies of Glaucoma. Investigator's Summary: The specific aims of this proposal are designed to develop stem cells from specific patients with glaucoma that can be used to develop the cell types that are lost due to this disease. Using these cells, we can study specific features of glaucoma and potentially develop new therapeutic options. Name of organization or government: Board of Regents of the University of Wisconsin System. Purpose of Grant or Assistance: National Glaucoma Research by Leonard Levin, M.D., Ph.D. Entitled: (G2012015) Redox Sulfhydryl Modifications As A Glaucoma Biomarker. Investigator's Summary: The irreversible loss of vision in glaucoma is from damage to the optic nerve causing death of nerve cells, but the details of the pathway by which the damage causes the death is still not known. We believe that there are one or more pivotal molecules which are critical to this pathway, based on how new drugs called 'phosphine-borane complexes' block it. Identifying these pivotal molecules could potentially allow glaucoma to be detected before it causes significant visual loss, help in monitoring the response to therapy, and even lead to new and better therapies for the disease.
	Name of organization or government: Johns Hopkins University. Purpose of Grant or Assistance: National Glaucoma Research by Derek Welsbie, M.D., Ph.D. Entitled: (G2012034) Genome-wide RNAi Screening in Retinal Ganglion Cells. Investigator's Summary: Vision loss from glaucoma is caused by the death of retinal ganglion cells, important nerve cells which carry vision from the eye to the brain. We are using gene therapy to try to better understand the signals which trigger these ganglion cells to die. In doing so, we hope to identify new drug targets that could be used to prevent cell death and vision loss. Name of organization or government: Johns Hopkins University. Purpose of Grant or Assistance: National Glaucoma Research by Shannath Merbs, M.D., Ph.D. Entitled: (G2012033) The Role of DNA Methylation in Ganglion Cell Death. Investigator's Summary: Although glaucoma is a common disease, little has been found in the way of a genetic contribution, suggesting that many genes and environmental factors may act together to cause the disease. In our study, we will look for 'epigenetic' changes (modifications to the DNA that can be caused, in part, by the environment) in an animal model of glaucoma. We will also test if manipulation of DNA methylation improves gangion cell survival. Name of organization or government: Johns Hopkins University. Purpose of Grant or Assistance: National Glaucoma Research by Zhiyong Yang, M.D., Ph.D. Entitled: (G2012032) Role of a Protein Kinase in Retinal Ganglion Cell Degeneration in Glaucoma. Investigator's Summary: The research proposed in this application will directly determine the potential value of a novel molecular target in the treatment of vision loss in glaucoma. In addition, a drug candidate that can block this target will be evaluated for its potential in the preservation of vision in a rodent model of glaucoma.
	Name of organization or government: University of South Florida. Purpose of Grant or Assistance: National Glaucoma Research by Chad Anthony Dickey, Ph.D. Entitled: (G2012071) Disrupting Chaperone/myocilin Complexes for Glaucoma. Investigator's Summary: We have determined that a class of proteins termed chaperones plays an important part in preserving another protein called myocilin. This is important because mutant myocilin accumulates in the distinct cells in the eye, killing them, and leading to glaucoma. We speculate that these chaperones will be excellent drug targets for primary open-angle glaucoma. Name of organization or government: Georgetown University. Purpose of Grant or Assistance: National Glaucoma Research by Alexander Theos, Ph.D. Entitled: (G2012025) Cell Biology of NMB in Pigmentary Glaucoma. Investigator's Summary: DBA/2J mice are an animal model of pigment dispersion syndrome (PDS) which is a precursor to glaucoma in humans. These mice harbor a putative loss of function mutation in the NMB gene which is responsible for this disease. We are proposing experiments that will characterize the cell biology of the NMB protein within pigmented cells of the eye in order to understand the functional role of NMB in normal cells, and, in addition, how loss of function of NMB causes PDS. Name of organization or government: Duke University Department of Ophthalmology. Purpose of Grant or Assistance: National Glaucoma Research by Paloma B. Liton, Ph.D. Entitled: (G2012022) Autophagy and Neurodegeneration in Glaucoma. Investigator's Summary: Under stress conditions, cells eat themselves to obtain the nutrients and energy required for survival. We will investigate whether self-eating protects the optic nerve against the insult produced by chronic high eye pressure.
	Name of organization or government: Mayo Clinic Jacksonville. Purpose of Grant or Assistance: National Glaucoma Research by Wing Lee, Ph.D. Entitled: (G2012011) Development of Novel Therapeutic for Inherited Glaucoma. Investigator's Summary: The study proposed aims at developing a new type of medicine for a common form glaucoma related to mutations in a gene called myocilin. It was found that some inherited mutations can change the structure of myocilin which can lead to toxicity and dysfunction of the eye cells responsible for regulating eye pressure. We attempt to identify drug-like chemical compounds that can bind to and stabilize the structure of mutated myocilin which subsequently may delay the disease onset or slow down disease progression by correcting abnormal changes at molecular level. Name of organization or government: Vanderbilt University. Purpose of Grant or Assistance: National Glaucoma Research by John Kuchtey, Ph.D. Entitled: (G2012007) Identification of Glaucoma Genes by Exome Sequencing. Investigator's Summary: The purpose of this study is to identify causative genetic mutations in two families with inherited primary congenital glaucoma (PCG). These families have already been screened for mutations in genes known to cause PCG, with no causative mutations found. Therefore, identification of the causative mutations in these families will result in the discovery of new glaucoma genes. Name of organization or government: University of Oklahoma Health Sciences Center. Purpose of Grant or Assistance: Macular Degeneration Research by Krysten Farjo, Ph.D. Entitled: (M2012057) A Novel Visual Cycle Inhibitor to Treat Macular Degeneration. Investigator's Summary: Macular degeneration is initiated and perpetuated by the accumulation of toxic vitamin A derivatives in the retina. Our research efforts are focused on developing a novel therapeutic agent which reduces the formation of toxic Vitamin A derivatives by inhibiting Vitamin A uptake into the retina. The ultimate goal is to develop a therapeutic agent that could be utilized to slow and prevent vision loss in patients with macular degeneration.
	Schedule F, Part II, Line 1, Column D: Name of organization: University of Antwerp (D) Purpose of Grant: National Glaucoma Research by Peter De Deyn, M.D., Ph.D. Entitled: (G2012028) Cerebrospinal Fluid Pressure at the Link Between Glaucoma and Alzheimer's Disease. Investigators Summary: Alzheimer's disease patients may be at higher risk of developing glaucoma. Both in patients and in a valid mouse model for Alzheimer's disease, we will study the underlying disease mechanisms responsible for this higher risk. We hypothesize that an increased cerebrospinal fluid pressure may be a major factor in this process. Grant Awarded: $100,000 University of Antwerp, Antwerp, Belgium.
	Name of organization or government: University of Texas Medical Branch. Purpose of Grant or Assistance: Macular Degeneration Research by Jiyang Cai, Ph.D., Ph.D. Entitled: (M2012012) Exosomal MicroRNA From the RPE. Investigator's Summary: Interactions between the retinal pigment epithelium (RPE) and their underlying choroidal blood vessels are critical in maintaining the structure and functions of the outer retina. We will examine how microvesicles released from the RPE can transfer genetic materials to the choroidal endothelial cells and modulate their functions. Results from our study can reveal a novel signaling mechanism with implications in age-related macular degeneration. Name of organization or government: Johns Hopkins University. Purpose of Grant or Assistance: Macular Degeneration Research by Noriko Esumi, M.D., Ph.D. Entitled: (M2012102) Mouse Models For Studying The Role Of Inflammation in AMD. Investigator's Summary: Among age-related diseases that develop on the conditions of aged tissues, age-related macular degeneration (AMD) is the leading cause of blindness in the elderly worldwide, and thought to result from abnormalities of the retinal pigment epithelium (RPE). Chronic inflammation has been recognized as a major underlying condition of aging in multiple tissues, and various environmental stimuli, such as oxidative stress and inflammatory molecules, converge upon a critical master regulator of inflammation. However, our understanding of the role of chronic inflammation and its master regulator in the RPE and AMD is still rudimentary, particularly in live animals, and therefore I propose to generate transgenic mouse models for two major purposes: 1) to address the biological role of this master regulator and its key modulator in the RPE of live animals, and 2) to ultimately evaluate whether modulation of these molecules can be a possible strategy for AMD treatment or prevention. Name of organization or government: Albert Einstein College of Medicine. Purpose of Grant or Assistance: Macular Degeneration Research by Wei Liu, Ph.D. Entitled: (M2012044) Efficient Differentiation of Retinal Pigment Epithelial Cells from hESC. Investigator's Summary: This research program aims at efficient generation of RPE cells in H1 hESC-derived cultures by supplementing Wnts and BMPs to retinal differentiation medium. This program is based on the recent findings that Wnt/beta-catenin and BMP signal transduction pathways promotes embryonic RPE development. The outcomes of this program are expected to develop a more efficient protocol for the generation of RPE cells in hESC or iPSC cultures and thus benefit the emerging stem cell-based strategy in treating and disease modeling of Age-related macular degeneration in which RPE cells are impaired and degenerated.
	Name of organization or government: Trustees of Boston University. Purpose of Grant or Assistance: Macular Degeneration Research by Matthew Nugent, Ph.D. Entitled: (M2012014) VEGF-ECM Interactions in Choroidal Neovascularization. Investigator's Summary: The unnatural growth of blood vessels, also called neovascularization, in the retina associated with age-related macular degeneration (AMD) is a leading cause of blindness in the world. Excess vascular endothelial growth factor, a protein that stimulates blood vessel growth, has been shown to be a major cause of neovascularization in AMD. In the present project, we propose to identify new ways that vascular endothelial growth factor activity is naturally controlled by interactions with the protein, fibronectin, so that we can target this pathway to more effectively treat neovascularization in the retina to prevent blindness. Name of organization or government: Vanderbilt University. Purpose of Grant or Assistance: Macular Degeneration Research by Ashwath Jayagopal, Ph.D. Entitled: (M2012067) In Vivo Molecular Imaging of Neovascular Age-related Macular Degeneration. Investigator's Summary: This proposal focuses on the development of nanoscale imaging agents capable of detecting biomarkers of early choroidal neovascularization in age-related macular degeneration (AMD). With the capability of molecular imaging, clinicians will be able to better treat AMD patients, through enhanced early detection, staging of disease, and monitoring of therapeutic response. Furthermore, this strategy will enable detailed imaging and therapeutic molecular target discovery in AMD to be conducted in preclinical and clinical studies. Name of organization or government: University of Miami. Purpose of Grant or Assistance: Macular Degeneration Research by Gaofeng Wang, Ph.D. Entitled: (M2012048) Determine the Existence and Sequence of ARMS2 Protein. Investigator's Summary: The gene ARMS2 is strongly associated with the risk to develop age-related macular degeneration. The existence and the sequence of ARMS2 protein have not yet been proven experimentally. We plan to prove the existence or non-existence of ARMS2 protein in human retina tissues.
	Name of organization or government: Vanderbilt University Medical Center. Purpose of Grant or Assistance: Macular Degeneration Research by Milam Brantley, M.D., Ph.D. Entitled: (M2012045) Quantitative Evaluation of Environmental Risk for Age-related Macular Degeneration. Investigator's Summary: The proposed research will examine how environment and genetics contribute to age-related macular degeneration (AMD). Using the cutting-edge technique of metabolomics, we will measure thousands of molecules called metabolites in the blood to investigate the environmental exposures that influence the likelihood that an individual will develop AMD. Determining the combination of metabolites and genetics that are associated with AMD will lead to a better understanding of the disease and personalized clinical care for AMD. Name of organization or government: University of Florida. Purpose of Grant or Assistance: Macular Degeneration Research by Haoyu Mao, Ph.D. Entitled: (M2012029) Treatment of Retinal Degeneration in a Mouse Model for Dry Age-related Macular Degeneration. Investigator's Summary: Currently, there is no effective treatment for the early form age-related macular degeneration (AMD)-dry AMD. Our mission is to develop new treatment for the dry form AMD. Therefore, our mission coincides with the mission of the AHAF. Name of organization or government: University of Miami. Purpose of Grant or Assistance: Macular Degeneration Research by Wei Li, Ph.D. Entitled: (M2012026) Anti-retinal Autoantibodies as Age-related Macular Degeneration Biomarkers. Investigator's Summary: Age-related macular degeneration (AMD) is a leading cause of irreversible blindness in industrialized countries. Biomarkers potentially could facilitate early diagnosis of the disease, which is important for early treatment to delay the disease or reduce its severity. This project will systematically identify anti-retinal autoantibodies in patient blood as biomarkers by a newly-developed technology for early diagnosis of AMD.

Schedule R IRS990ScheduleR

Form990 Schedule R Part I Form990ScheduleRPartI (2 entries)

Address Line1AddressUS/AddressLine1	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	EINEIN	Primary ActivitiesPrimaryActivities	Legal Domicile StateLegalDomicileState	Total IncomeTotalIncome	EOY AssetsEOYAssets	Direct Controlling Entity NADirectControllingEntityNA
National Development LLC
22512 Gateway Center Drive	Clarksburg	MD	20871	237337229	Property rental and managment	MD	902075	5136566	N/A
American Health Assistance LLC
22512 Gateway Center Drive	Clarksburg	MD	20871	237337229	Owner of AHAF headquarters	MD		4333285	N/A